Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis.

Literature DB >> 21282421

Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis.

Zahoor Ahmad¹, Austin Minkowski, Charles A Peloquin, Kathy N Williams, Khisimuzi E Mdluli, Jacques H Grosset, Eric L Nuermberger.

Abstract

DC-159a is a new fluoroquinolone with more potent in vitro activity than available fluoroquinolones against both drug-susceptible and fluoroquinolone-resistant Mycobacterium tuberculosis. Here, we report that DC-159a displays pharmacokinetics similar to those of moxifloxacin yet is more active than moxifloxacin during both the initial and continuation phases of treatment in a murine model. These results warrant further preclinical evaluation of DC-159a in selected drug combinations against drug-susceptible and fluoroquinolone-resistant tuberculosis.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2011 PMID： 21282421 PMCID： PMC3067133 DOI： 10.1128/AAC.01514-10

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

11 in total

1. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis.

Authors: Yanmin Hu; Anthony R M Coates; Denis A Mitchison
Journal: Antimicrob Agents Chemother Date: 2003-02 Impact factor: 5.191

2. Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.

Authors: Muhammad Malik; Karl Drlica
Journal: Antimicrob Agents Chemother Date: 2006-08 Impact factor: 5.191

3. In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.

Authors: Areeya Disratthakit; Norio Doi
Journal: Antimicrob Agents Chemother Date: 2010-04-05 Impact factor: 5.191

4. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.

Authors: William J Burman; Stefan Goldberg; John L Johnson; Grace Muzanye; Melissa Engle; Ann W Mosher; Shurjeel Choudhri; Charles L Daley; Sonal S Munsiff; Zhen Zhao; Andrew Vernon; Richard E Chaisson
Journal: Am J Respir Crit Care Med Date: 2006-05-04 Impact factor: 21.405

5. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.

Authors: Sandeep Tyagi; E Nuermberger; T Yoshimatsu; K Williams; I Rosenthal; N Lounis; W Bishai; J Grosset
Journal: Antimicrob Agents Chemother Date: 2005-06 Impact factor: 5.191

Review 6. Fluoroquinolones, tuberculosis, and resistance.

Authors: Amy Sarah Ginsburg; Jacques H Grosset; William R Bishai
Journal: Lancet Infect Dis Date: 2003-07 Impact factor: 25.071

7. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study.

Authors: Anne von Gottberg; Keith P Klugman; Cheryl Cohen; Nicole Wolter; Linda de Gouveia; Mignon du Plessis; Ruth Mpembe; Vanessa Quan; Andrew Whitelaw; Rena Hoffmann; Nelesh Govender; Susan Meiring; Anthony M Smith; Stephanie Schrag
Journal: Lancet Date: 2008-03-21 Impact factor: 79.321

Review 7. Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.

Authors: Klaudia T Angula; Lesetja J Legoabe; Richard M Beteck
Journal: Pharmaceuticals (Basel) Date: 2021-05-13

7 in total

Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis.

1. Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis.

2. Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.

3. In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.

4. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis.

5. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis.

Review 6. Fluoroquinolones, tuberculosis, and resistance.

7. Emergence of levofloxacin-non-susceptible Streptococcus pneumoniae and treatment for multidrug-resistant tuberculosis in children in South Africa: a cohort observational surveillance study.

8. A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.

9. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice.

10. In vitro and in vivo antibacterial activities of DC-159a, a new fluoroquinolone.

1. Silver ciprofloxacin (CIPAG): a successful combination of chemically modified antibiotic in inorganic-organic hybrid.

Review 2. Current prospects for the fluoroquinolones as first-line tuberculosis therapy.

3. Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis.

4. Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.

Review 5. New Drugs for the Treatment of Tuberculosis.

Review 6. Advances in Key Drug Target Identification and New Drug Development for Tuberculosis.

Review 7. Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.